Navigation Links
Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
Date:5/3/2012

ble bowel syndrome, rheumatoid arthritis and glaucoma, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... , Aug. 30, 2014  Boston Scientific has ... Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, ... investigating vagus nerve stimulation (VNS) for the treatment ... Professor of Therapeutics and Cardiology and Director of ... de la Sante et de la Recherche Medicale ...
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
... Jan. 25, 2012  Amorcyte, LLC, a NeoStem, Inc. ... announces the enrollment of the first patient in ... myocardial infarction. The study is a multicenter, randomized, ... and efficacy of infarct-related artery infusion of AMR-001, ...
... hosting a free webinar on the upcoming changes to the ... and is intended to address the growing number of questions ... (Logo: http://photos.prnewswire.com/prnh/20110405/NE77664LOGO ) "We,ll do ... the current status and upcoming changes, as well as insight ...
Cached Medicine Technology:Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 2Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 3Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 4FREE Webinar: Revision of the In Vitro Diagnostic Directive 2
(Date:8/30/2014)... Zensah®, the leader in compression technology and ... as a best-seller within golf and tennis. Golfers and tennis ... enjoy most by using the compression elbow sleeve to help ... a condition that causes pain on the inner side of ... to the bony bump on the inside of your elbow. ...
(Date:8/30/2014)... 31, 2014 Atlanta based automotive group ... help raise money and awareness for ALS by participating ... Managers, staff, and even Vice President Jimmy Ellis all ... and can be viewed on their Youtube page; ... challenge, general managers and staff also took the opportunity ...
(Date:8/30/2014)... Recently, Top 10 Best SEO Hosting ... announced that BlueHost and JustHost ( http://www.justhost.com/track/seohosts ) ... to buy high quality web hosting. , ... web host companies who outperform their competitors on ... support.” A spokesman for Top 10 Best SEO ...
(Date:8/30/2014)... UWDress.com, a distinguished wedding dress supplier, has gained ... of fashionable outfits. Recently, the company has unveiled its beautiful ... autumn special offer, all these brand new products are provided ... “We are excited to unveil the new and trendy bridesmaid ... products are available at low prices now. The purpose of ...
(Date:8/30/2014)... (PRWEB) August 31, 2014 Recently, iFitDress.com, ... announced its new designs of classy bridesmaid dresses ... big discounts (from 22 percent off to 62 percent ... these extremely beautiful items. , True enough, iFitDress.com ... women’s special occasion gowns. The company persists in making ...
Breaking Medicine News(10 mins):Health News:Relieve Golfers and Tennis Elbow Pain with the Zensah® Compression Elbow Sleeve 2Health News:Jim Ellis Automotive Group Take the ALS Ice Bucket Challenge 2Health News:Great Web Hosting Suppliers Recently Recommended by Top10BestSEOHosting.com 2Health News:UWDress.com’s Beautiful Collection Of “Flowy Bridesmaid Dresses” Released 2Health News:Classy Bridesmaid Dresses Announced By Loved Online Supplier iFitDress.com 2
... (Pink Sheets: BPYT) ("Bioponic"), an innovative provider of ... (CAM) and nutraceutical markets, announced today that it ... Financial,Communications Corporation, as its investor relations representative. ... and approximately 62% of U.S.,adults are using some ...
... disease, study finds , , THURSDAY, Oct. 4 (HealthDay News) -- ... the heart,s left main artery should take special care of ... sisters of someone with such problems are 2.5 times more ... the siblings of patients with heart disease not related to ...
... ROCKVILLE, Md., Oct. 4 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases,announced today ... Officer,will present a Company overview at the Biotechnology ... Palace Hotel, San Francisco,California, October 9-11, 2007. Mr. ...
... Oct. 4 According to the,November 2006 Rand ... alone costs about $6.4 billion a year nationally ... If another amnesty were adopted,tens of millions of ... be added within 20 years to the U.S. ...
... The National Confectioner,s,Association has noted that up to ... this in mind, Halloween is a perfect time ... children. "Since candy and Halloween go together...Consider ... can enjoy chocolate and,lollipops on occasion as long ...
... following is a,statement by Michael Bender, director of The ... Food and Drug Administration and its various,expert groups, and ... years to present a balanced and clear message in ... there is,there is enough mercury in certain fish to ...
Cached Medicine News:Health News:Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2Health News:Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 3Health News:Cardiac Artery Trouble Boosts Family Heart Risk 2Health News:Cardiac Artery Trouble Boosts Family Heart Risk 3Health News:EntreMed to Present at the Bio 2007 Investor Forum 2Health News:Message for Activists at Latino National Congreso Convention: Amnesty Will Exacerbate National Problems and Turn the U.S. into Another Mexico 2Health News:Parents can Help Young Superheroes Battle Cavities on Halloween Night 2Health News:New Fish Advice Throws Baby Out With the Bath Water, Says Mercury Watchdog Group 2
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... The Raindrop® medication nebulizer achieves optimum ... MMAD particle size range is 1.04-1.10 µ ... compressor or air outlet., ,As the ... gives healthcare providers the assurance of proven ...
... the need for makeshift, modified nebulizer setups ... time gathering parts when your patient is ... deliver the utmost in Heliox rescue therapy. ... fast becoming the standard of care in ...
Medicine Products: